- Home
- A-Z Publications
- Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
- Previous Issues
- Volume 11, Issue 5, 2011
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) - Volume 11, Issue 5, 2011
Volume 11, Issue 5, 2011
-
-
Editorial [Hot Topic: Emerging Therapeutic Targets and Agents for Pancreatic Cancer Therapy (Guest Editor: Dr. Felix Ruckert)]
Authors: Susanne Sebens and Holger KalthoffPancreatic ductal adenocarcinoma (PDAC) is still one of the most malignant tumor diseases exhibiting an unfavorable prognosis. It is well known for its late presentation, the aggressive progression and metastatic spread, along with its poor outcome [1, 2]. In Western countries, PDAC is the fourth leading cause of cancer related death with an overall 5-year survival rate less than 1 % and most patients dying within one year [3]. The Read More
-
-
-
An Update on Molecular Research of Pancreatic Adenocarcinoma
Introduction: This review provides an overview of the molecular mechanisms and pathways known to enhance development and progression of pancreatic ductal adenocarcinoma (PDAC). Results: Today, the concept that progression of epithelial precursor lesions leads to invasive PDAC as a result of accumulating mutation in K-ras, p16INK4A, p53 and Smad4 is widely accepted. Multiple signaling pathways that PDAC utilizes to Read More
-
-
-
Combination Therapy for the Treatment of Pancreatic Cancer
Authors: William Greenhalf and Amy ThomasTreatment of pancreatic cancer should be a relatively simple clinical problem, all that is needed is to find the features of pancreatic cancer cells that distinguish them from normal cells and target these differences. This is the basis of current therapies including gemcitabine and 5-FU which target DNA synthesis. Unfortunately, cancer cells become resistant to these therapies: By exclusion of drugs from cancer cells; by chang Read More
-
-
-
Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer
Authors: Simon Rieder, Christoph W. Michalski, Helmut Friess and KleeffInsulin-like growth factor-1 (IGF-1) leads via its receptor IGF-1R to the activation of the PI3K/Akt pathway, providing antiapoptotic signals to pre-malignant and malignant cells. In pancreatic cancer, IGF-1 and its receptor are constitutively overexpressed. Mammalian target of rapamycin (mTOR) is the main mediator of mitogenic stimuli transduced by PI3K/Akt. Interestingly, inhibition of mTOR activates PI3K/Akt by up-reg Read More
-
-
-
Aptamers: Potential Applications to Pancreatic Cancer Therapy
Authors: Kristy L. Rialon and Rebekah R. WhiteThere is an unquestionable need for more effective therapies for pancreatic cancer. Aptamers are single-stranded DNA or RNA oligonucleotide ligands whose 3-dimensional structures are dictated by their sequences. Aptamers have been generated against numerous purified protein targets using an iterative in vitro selection technique known as Systematic Evolution of Ligands by EXponential enrichment (SELEX). Several bioc Read More
-
-
-
Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
More LessThe Neuropilin receptors are increasingly recognized as receptors for vascular endothelial growth factors like VEGF-A and VEGF-C as well as other important growth factors like HGF and FGF in human vasculature and in tumor cells. More and more studies show an important role of Neuropilin in cancer biology suggesting that these transmembrane proteins might be an emerging target for new therapies in different subsets of ca Read More
-
-
-
Genes Associated with Epithelial-Mesenchymal Transition: Possible Therapeutic Targets in Ductal Pancreatic Adenocarcinoma?
Authors: Hubert G. Hotz, Birgit Hotz and Heinz-Johannes BuhrEpithelial to mesenchymal transition (EMT) is a biological process that allows well-differentiated, polarized epithelial cells to undergo a conversion to motile, unpolarized mesenchymal cells. EMT plays crucial roles during implantation, embryogenesis, and organ development (Type 1 EMT), is associated with tissue regeneration and organ fibrosis (Type 2 EMT), and involved in cancer invasion, metastasis, and drug resistance (Ty Read More
-
-
-
Targeting Phosphoinositide 3-Kinase Pathways in Pancreatic Cancer - from Molecular Signalling to Clinical Trials
Authors: Marco Falasca, Federico Selvaggi, Richard Buus, Sara Sulpizio and Charlotte E. EdlingPancreatic cancer has one of the poorest prognoses among all cancers partly because of its silent nature and tendency for late discovery but also because of its persistent resistance to chemotherapy. At present there are very limited treatment alternatives for pancreatic cancer, hence the need to develop novel and more efficient drugs. It is well known that mutations in K-Ras oncogene accumulate early in the disease progr Read More
-
-
-
Anti-Angiogenic Agents in Pancreatic Cancer: A Review
Authors: Murwarid M. Assifi and Oscar J. HinesPancreatic cancer is the fourth leading cause of cancer related death in the United States, with a 5-year survival of less than five percent. Since the majority of patients have locally advanced or metastatic disease at the time of diagnosis, there has been little progress made to extend survival. For over ten years, chemotherapy with gemcitabine has been standard treatment for those patients with advanced pancreatic cancer, p Read More
-
-
-
Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Authors: Nicholas J. Zyromski and Patrick B. WhiteObesity, now a worldwide epidemic, causes myriad medical problems. One of the most significant obesity-related problems is the well-recognized relationship between obesity and various malignancies, including pancreatic cancer. Pancreatic cancer is a devastating disease - the annual death rate nearly approximates its incidence. While surgical extirpation provides the best chance at long term survival, systemic therapy is lar Read More
-
-
-
Resveratrol and Its Analogues: Promising Antitumor Agents
Authors: Xianfeng-Huang and Hai-Liang ZhuResveratrol, a well-know natural product and a major component in grape, has attracted considerable attention as one of the most promising cancer during the past decade. Many studies have established that resveratrol can exert a broad range of biological activities including ceramide-mediated proapoptotic, antineoplastic, apoptosis-inducing, etc. Most important, resveratrol has been identified as an effective candidate Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
Most Read This Month
Article
content/journals/acamc
Journal
10
5
false
en
